Abstract 216: Hospitalizations of Patients With Heart Failure and Reduced Ejection Fraction Treated With Sacubitril/Valsartan (S/V) vs. Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker (ACEI/ARB) [Session Title: Poster Session PM]

Conclusions: Compared to ACEI/ARB, S/V therapy among patients with HFrEF is related to reduction of costly hospitalizations, which may translate to potential cost saving in HF care. The lack of HF hospitalization significance may represent the disparity in the sample size. Sponsorship: The study was funded by Novartis Pharmaceuticals Corp., East Hanover, NJ.

Source: Circulation: Cardiovascular Quality and Outcomes - April 5, 2018 Category: Cardiology Authors: Chang, C., Song, X., Nguyen, A., Smith, D., Choi, M., Duffy, C. Tags: Session Title: Poster Session PM Source Type: research